VISITECT-CD4-LFA shows 98% sensitivity for CD4 count detection in patients with HIVNew test shows high accuracy for monitoring HIV disease progression

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases Published November 4, 2026 Study authors: Gebremeskele Behailu Taye, Tesfaye Haile, Hammeso Workineh Woldeselassie, Churiso Gemechu PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that VISITECT-CD4-LFA meets the 90% sensitivity requirement for point-of-care CD4 testing in advanced HIV disease.

This meta-analysis evaluates the diagnostic accuracy of the VISITECT-CD4-LFA lateral-flow assay compared to flow cytometry for identifying CD4 counts in patients with HIV. The analysis included a total sample size of 6962. The primary outcomes were sensitivity and specificity, with secondary outcomes including area under the curve (AUC).

The meta-analysis reported a sensitivity of 98% (95% CI: 94-99%) for the VISITECT-CD4-LFA. Specificity was reported at 71% (95% CI: 56-85%). For capillary blood, sensitivity was 96% (95% CI: 93-97%), and for venous blood, sensitivity was 99% (95% CI: 93-100%). The reported AUC was 0.95.

Limitations noted by the authors include the fact that specificity fell below the 80% target performance profile and a need for more research in South American and Asian populations. Despite the lower specificity, the assay meets the 90% sensitivity requirement for point-of-care CD4 tests for advanced HIV disease. It may facilitate timely screening and prophylaxis in decentralized settings.

Managing HIV requires accurate tracking of CD4 counts, which are cells that help the body fight infection. For people living in remote areas, getting these tests can be difficult. A new rapid test, called the VISITECT-CD4-LFA, was tested to see if it could provide reliable results quickly in these settings.

The analysis of data from nearly 7,000 people showed the test is highly sensitive. It correctly identified CD4 levels in 98 percent of cases. It performed well with both capillary blood (from a finger prick) and venous blood (from a vein). This high sensitivity means the test is very good at catching the results it is looking for.

While the test is highly sensitive, its specificity—the ability to correctly identify those without the condition—was lower at 71 percent. This fell below the target of 80 percent. Because the data comes from a meta-analysis, more research is still needed in South American and Asian populations to confirm how it works for everyone.

What this means for you:

The rapid test is highly sensitive for tracking CD4 counts, making it useful for monitoring HIV in remote areas.

Common questions

How accurate is this new rapid test for HIV patients?

The test shows a high sensitivity of 98 percent, meaning it is very good at correctly identifying CD4 levels. It performed well with both capillary blood (96 percent) and venous blood (99 percent). However, its specificity was 71 percent, which is lower than the 80 percent target.

Who can benefit from using this rapid test?

This test is especially helpful for people with HIV in decentralized or remote settings. Because it is a point-of-care test, it can help doctors provide faster screening and treatment in places where standard laboratory equipment is not easily available.

Are there any limitations to this test's results?

The test's specificity fell below the 80 percent target. Additionally, the researchers noted that more research is needed specifically in South American and Asian populations to ensure the results are consistent across different groups of people.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedNov 2026

PMID42700888

View Original Abstract ↓

OBJECTIVE: This systematic review and meta-analysis aimed to evaluate the pooled performance of the VISITECT-CD4 advanced disease lateral-flow assay (VISITECT-CD4-LFA) for diagnosing advanced HIV disease (AHD). METHODS: A search was conducted in PubMed, EMBASE, Google Scholar, and Scopus up to February 2, 2026, to identify studies that evaluated VISITECT-CD4-LFA. Methodological quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Meta-analysis was conducted using a bivariate random-effects model to estimate pooled sensitivity and specificity compared to flow cytometry. RESULTS: Ten studies were included, comprising 6962 people with HIV. Pooled sensitivity and specificity were 98% (95% CI: 94-99%) and 71% (95% CI: 56-85%), respectively, with an area under the curve (AUC) of 0.95. Subgroup analysis revealed that VISITECT-CD4-LFA from capillary blood had similar sensitivity (96%, 95% CI: 93-97%) to venous blood (99%, 95% CI: 93-100%). CONCLUSIONS: VISITECT-CD4-LFA meets the ≥90% sensitivity requirement specified in the target product profile (TPP) for point-of-care CD4 tests for AHD. With robust sensitivity using both venous and capillary blood, it has the potential to facilitate timely screening and prophylaxis for opportunistic infections in decentralized settings. The assay's pooled specificity fell slightly below the ≥80% TTP target. Further research is needed for South American and Asian populations, with strategies to boost specificity. PROSPERO REGISTRATION: CRD420251272180.

VISITECT-CD4-LFA shows 98% sensitivity for CD4 count detection in patients with HIVNew test shows high accuracy for monitoring HIV disease progression

Common questions

Study Details

Candidiasis prevalence of 13.46% and Cryptococcal meningitis of 3.15% among HIV-positive individuals

New data shows prevalence of fungal infections in HIV patients

Clinical research that matters. Delivered to your inbox.

VISITECT-CD4-LFA shows 98% sensitivity for CD4 count detection in patients with HIVNew test shows high accuracy for monitoring HIV disease progression

Common questions

More on HIV

Study Details

Candidiasis prevalence of 13.46% and Cryptococcal meningitis of 3.15% among HIV-positive individuals

New data shows prevalence of fungal infections in HIV patients

Clinical research that matters. Delivered to your inbox.

Related in Infectious Disease

From Other Specialties